Stevens-Johnson Syndrome After Armodafinil Use
- PMID: 29734973
- PMCID: PMC5940442
- DOI: 10.5664/jcsm.7132
Stevens-Johnson Syndrome After Armodafinil Use
Abstract
We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of armodafinil. Although this rare and life-threatening reaction is listed on armodafinil's label, no cases have been reported in the literature. This case, in addition to an update of the drug's label after post-marketing research, both support the link between armodafinil and SJS. Providers should maintain a high clinical suspicion for SJS when starting therapy to minimize associated morbidity and mortality by discontinuing armodafinil at the onset of first symptoms.
Keywords: Stevens-Johnson syndrome; armodafinil.
© 2018 American Academy of Sleep Medicine.
Figures
References
-
- Wang W, Lazar A. Lichenoid and interface dermatitis. In: Calonje E, Brenn T, Lazar A, McKee P, editors. McKee's Pathology of the Skin with Clinical Correlations. 4th ed. Elsevier Limited; 2012. pp. 241–245.
-
- Darlenski R, Kazandjieva J, Tsankov N. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. Clin Dermatol. 2015;33(5):538–541. - PubMed
-
- Frazer, PA: Cephalon, Inc.; 2010. Nuvigil [package insert]
-
- North Wales, PA: Cephalon, Inc.; 2017. Nuvigil (armodafi nil) Tablets [highlights of prescribing information] Reference ID: 4052668.
-
- Dodiuk-Gad R, Chung W, Valeryrie-Allanore L, Shear N. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–493. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources